KX 01

Drug Profile

KX 01

Alternative Names: KX-2391; KX01

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kinex Pharmaceuticals
  • Developer Athenex; Hanmi Pharmaceutical; Kinex Pharmaceuticals; PharmaEssentia Corporation
  • Class Acetamides; Antineoplastics; Morpholines; Pyridines; Skin disorder therapies; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Caspase stimulants; Interleukin 2 inhibitors; Keratinocyte inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Src-Family kinase inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Actinic keratosis
  • Phase II Psoriasis
  • Phase I/II Solid tumours
  • No development reported Acute myeloid leukaemia; Prostate cancer

Most Recent Events

  • 20 Feb 2018 Updated efficacy, adverse events and pharmacokinetics data from a phase II trial in Actinic keratosis released by Athenex
  • 14 Feb 2018 Athenex completes enrolment in two phase III trials for Actinic keratosis in USA (Topical)
  • 11 Dec 2017 Almirall and Athenex agree to co-promote and co-develop KX 01 in Europe, Russia and USA for actinic keratosis and other skin conditions
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top